Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Tripeptides – e.g. – tripeptide thyroliberin – etc.
Reexamination Certificate
2011-03-15
2011-03-15
Tsang, Cecilia (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Tripeptides, e.g., tripeptide thyroliberin , etc.
Reexamination Certificate
active
07906619
ABSTRACT:
The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula Iand the pharmaceutically salts and hydrates thereof.The variables R1-R9, R16, R18, R19, n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
REFERENCES:
patent: 6872805 (2005-03-01), Campbell et al.
patent: 6908901 (2005-06-01), Bailey et al.
patent: 6995174 (2006-02-01), Wang et al.
patent: 7041698 (2006-05-01), Ripka et al.
patent: 7176208 (2007-02-01), Nakajima et al.
patent: 2004/0002448 (2004-01-01), Tsantrizos et al.
patent: 2004/0048802 (2004-03-01), Ripka et al.
patent: 2004/0077551 (2004-04-01), Campbell et al.
patent: 2004/0224900 (2004-11-01), Bailey et al.
patent: 2006/0019905 (2006-01-01), Bailey et al.
patent: 2006/0046965 (2006-03-01), Bailey et al.
patent: 2006/0199773 (2006-09-01), Sausker et al.
patent: 2007/0010455 (2007-01-01), Hewawasam et al.
patent: 2007/0093414 (2007-04-01), Carini et al.
patent: 2007/0099825 (2007-05-01), D'Andrea et al.
patent: 2010/0216725 (2010-08-01), Phadke et al.
patent: 0260926 (2002-08-01), None
patent: 03099274 (2003-12-01), None
patent: 03099316 (2003-12-01), None
patent: 2004043339 (2004-05-01), None
patent: 2004072243 (2004-08-01), None
patent: 2004094452 (2004-11-01), None
patent: 2004103996 (2004-12-01), None
patent: 2004113365 (2004-12-01), None
patent: WO 2004/103996 (2004-12-01), None
patent: 2005007681 (2005-01-01), None
patent: 2005028501 (2005-03-01), None
patent: 2005037214 (2005-04-01), None
patent: 2005046712 (2005-05-01), None
patent: 2005051410 (2005-06-01), None
patent: 2005054430 (2005-06-01), None
patent: 2005070955 (2005-08-01), None
patent: 2005073216 (2005-08-01), None
patent: 2005090383 (2005-09-01), None
patent: 2005095403 (2005-10-01), None
patent: 2006007700 (2006-01-01), None
patent: 2006007708 (2006-01-01), None
patent: 2006020276 (2006-02-01), None
patent: 2006033878 (2006-03-01), None
patent: 2006086381 (2006-08-01), None
patent: 2006096652 (2006-09-01), None
patent: 2007005838 (2007-01-01), None
patent: 2007009109 (2007-01-01), None
patent: 2007009227 (2007-01-01), None
patent: 2007014919 (2007-02-01), None
patent: 2007015824 (2007-02-01), None
patent: 2007030656 (2007-03-01), None
patent: 2007044893 (2007-04-01), None
International Search Report for WO 2008/008502.
Llinas-Brunet, et al, “A Systematic Approach to the Optimization of Substrate-Based Inhibitors of the Hepatitis C Virus NS3 Protease: Discovery of Potent and Specific Tripeptide Inhibitors,” J. Med. Chem. 47:6584-6594 (2004).
Andrews, et al., “Pyrrolidine-5,5-trans-lactams. 2. The Use of X-ray Crystal Structure Data in the Optimization of P3 and P4 Substituents,” Organic Letters, 4(25): 4479-4482 (2002).
Arasappan, et al., “Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P2 Moiety with improved potency,” Bioorganic and Medicinal Chemistry Letters, 15: 4180-4184 (2005).
Barbato, et al., Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain, The EMBO Journal, 19(6): 1995-1206 (2000).
Di Marco, et al., “Inhibition of the Hepatitis C Virus NS3/4A Protease,” The Journal of Biological Chemistry, 275(10): 7152-7157 (2000).
Liu, et al., “Hepatitis C NS3 protease inhibition by peptide-a-ketoamide inhibitors: kinetic mechanism and structure,” Archives of Biochemistry and Biophysics 421: 207-216 (2004).
Ontoria, et al., “The Design and Enzyme-Bound Crystal Structure of Indoline Based Peptidomimetic Inhibitors of Hepatitis C Virus NS3 Protease,” J. Med. Chem. 47: 6443-6446 (2004).
Slater, et al., “Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 Urea Leads to Potent Intracellular Inhibitors of Hepatitis C Virus NS3/4A Protease,” Organic Letters, 5(24): 4627-4630 (2003).
Venkatraman, et al., Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethyllethyl)amino]carbonyl] amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection, J. Med. Chem. 49: 6074-6086 (2006).
Agarwal Atul
Phadke Avinash
Wang Xiangzhu
Zhang Suoming
Achillion Pharmaceuticals, Inc.
Cantor & Colburn LLP
Heard Thomas S
Tsang Cecilia
LandOfFree
4-amino-4-oxobutanoyl peptides as inhibitors of viral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-amino-4-oxobutanoyl peptides as inhibitors of viral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-amino-4-oxobutanoyl peptides as inhibitors of viral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2647756